A Randomized, Double-Blind, Placebo-Controlled Single Intravenous and Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Apimostinel (Primary) ; Apimostinel (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Naurex
- 17 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 May 2015 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov
- 27 Nov 2013 Planned End Date changed from 1 Jun 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.